RALEIGH, NC / ACCESSWIRE / February 25, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the publication of encouraging data in the journal Critical Care Explorations, accessible online here, on the use of larazotide to treat pediatric patients with multisystem inflammatory syndrome in children (MIS-C) resulting from COVID-19. MIS-C is a rare but severe and potentially life-threatening condition that usually develops in children weeks to months after they have experienced a mild or even asymptomatic case of COVID-19.
